Sanofi $SNY Stock Sold by EagleClaw Capital Managment LLC

EagleClaw Capital Managment LLC lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 60.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,875 shares of the company’s stock after selling 27,535 shares during the period. EagleClaw Capital Managment LLC’s holdings in Sanofi were worth $737,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in SNY. Moors & Cabot Inc. increased its position in Sanofi by 4.4% in the 3rd quarter. Moors & Cabot Inc. now owns 10,497 shares of the company’s stock valued at $433,000 after acquiring an additional 446 shares during the period. Allworth Financial LP boosted its position in Sanofi by 4.7% during the 3rd quarter. Allworth Financial LP now owns 9,666 shares of the company’s stock worth $412,000 after acquiring an additional 433 shares during the period. Fifth Third Bancorp boosted its position in Sanofi by 28.3% during the 3rd quarter. Fifth Third Bancorp now owns 27,533 shares of the company’s stock worth $1,135,000 after acquiring an additional 6,072 shares during the period. Ritholtz Wealth Management grew its stake in shares of Sanofi by 48.3% in the third quarter. Ritholtz Wealth Management now owns 45,685 shares of the company’s stock worth $1,884,000 after purchasing an additional 14,880 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in shares of Sanofi in the third quarter worth $3,715,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wolfe Research began coverage on Sanofi in a report on Friday, October 9th. They set a “peer perform” rating on the stock. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, November 7th. Deutsche Bank reiterated a “buy” rating on shares of Sanofi in a research report on Tuesday, September 29th. BNP Paribas Exane raised shares of Sanofi from a “neutral” rating to an “outperform” rating and set a $57.00 target price on the stock in a research note on Monday. Finally, UBS Group reissued a “neutral” rating on shares of Sanofi in a research note on Thursday, September 17th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat, Sanofi presently has a consensus rating of “Hold” and an average price target of $53.00.

Sanofi Stock Performance

SNY opened at $48.37 on Friday. The business has a 50 day moving average price of $42.68 and a two-hundred day moving average price of $44.38. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.12 and a quick ratio of 0.27. The company has a market capitalization of $117.27 billion, a price-to-earnings ratio of 23.95, a price-to-earnings-growth ratio of 1.33 and a beta of 0.31. Sanofi has a 1-year low of $39.07 and a 1-year high of $52.67.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.56 by $0.48. Sanofi had a return on equity of 15.16% and a net margin of 8.70%. The company had revenue of $17.25 billion for the quarter, compared to analysts’ expectations of $14.30 billion. During the same period last year, the firm earned $2.91 EPS. The firm’s revenue for the quarter was up 16.2% on a year-over-year basis. Research analysts predict that Sanofi will post 5.07 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.